



Company Update

[Oncosil Medical \(OSL\) | BUY: The CT-scans indicate good progress](#)

Life Sciences Tools and Services TP \$0.38 **BUY**

Shane Storey +61 7 3212 1351

We maintain our BUY rating on Oncosil Medical and are sticking with our 12-month price target of \$0.38 per share. The company's OncoPac-1 clinical trial in pancreatic cancer has made further progress, reporting its first safety and tumour response results at the EANM 2017 Congress in Vienna. In this report we review those data briefly and reiterate the salient feedback from our consultants and literature sources that support our positive view on the OncoSil™ asset. Although the EANM data is very early and uncontrolled, it re-validates the product concept and the development program being pursued. In 12 months' time Oncosil could be making modest sales in Europe and enrolling a global, pivotal study under an FDA-approved IDE – an entirely different valuation footing to what investors see today. Hence our continued positivity on OSL shares.

Unsubscribe. This email has been provided to you as part of the Wilsons research offering via the **Wilson's Client Portal website and/or Wilson's App**. If you would like to change which emails you receive or remove yourself from this list, please amend the "Subscriptions" preferences with the Research section of the Client Portal website or the "Settings"/"Subscriptions" preferences of the Wilson's App. If you would like to change your email address, please email your adviser (or call 1300 655 015).

Disclaimer. This document has been prepared by Wilsons Advisory and Stockbroking Limited (ACN 010 529 665; AFSL 238 375) ("Wilson"). While Wilsons believes the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. To the extent permitted by law, Wilsons disclaims all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage) however caused, which may be suffered or arise directly or indirectly in respect of such information. Any projections contained in this communication are estimates only. Such projections are subject to market influences and contingent upon matters outside the control of Wilsons and therefore may not be realised in the future. Past performance is not an indication of future performance.

The advice contained in this document is general advice. It has been prepared without taking account of any person's objectives, financial situation or needs and because of that, any person should, before acting on the advice, consider the appropriateness of the advice, having regard to the client's objectives, financial situation and needs. If the advice relates to the acquisition, or possible acquisition, of a particular financial product, the client should obtain a Product Disclosure Statement relating to the product and consider it before making any decision about whether to acquire the product. This communication is not to be disclosed in whole or part or used by any other party without Wilsons' prior written consent.

This document does not constitute an offer or invitation to purchase any securities and should not be relied upon in connection with any contract or commitment whatsoever.

Wilson's and Wilson's Corporate Finance Limited (ABN 65 057 547 323; AFSL 238 383) and their associates may have received and may continue to receive fees from any company or companies referred to in this document (the "Companies") in relation to corporate advisory, underwriting or other professional investment services. Please see relevant Wilson's disclosures at wilsonsadvisory.com.au/Disclosures. In addition, the directors of Wilson's advise that at the date of this report they and their associates may have relevant interests in the securities of the Companies.

Copyright © 2017 Wilson's. All rights reserved.